196 related articles for article (PubMed ID: 38365809)
1. Cross-talk between disulfidptosis and immune check point genes defines the tumor microenvironment for the prediction of prognosis and immunotherapies in glioblastoma.
Zhou Y; Qin X; Hu Q; Qin S; Xu R; Gu K; Lu H
Sci Rep; 2024 Feb; 14(1):3901. PubMed ID: 38365809
[TBL] [Abstract][Full Text] [Related]
2. The disulfidptosis-related signature predicts prognosis and immune features in glioma patients.
Wang X; Yang J; Yang F; Mu K
Sci Rep; 2023 Oct; 13(1):17988. PubMed ID: 37864127
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtypes of disulfidptosis-regulated genes and prognosis models for predicting prognosis, tumor microenvironment infiltration, and therapeutic response in hepatocellular carcinoma.
Qu J; Guan H; Zheng Q; Sun F
Int J Biol Macromol; 2024 Mar; 261(Pt 1):129584. PubMed ID: 38246443
[TBL] [Abstract][Full Text] [Related]
4. Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
Li P; Wang S; Wan H; Huang Y; Yin K; Sun K; Jin H; Wang Z
Front Immunol; 2024; 15():1258475. PubMed ID: 38352883
[TBL] [Abstract][Full Text] [Related]
5. Integrated multiomic analysis reveals disulfidptosis subtypes in glioblastoma: implications for immunotherapy, targeted therapy, and chemotherapy.
Yang X; Cai Z; Wang C; Jiang C; Li J; Chen F; Li W
Front Immunol; 2024; 15():1362543. PubMed ID: 38504986
[TBL] [Abstract][Full Text] [Related]
6. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
7. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
8. Investigating the prognostic value of constructing disulfidptosis-related gene models for lung adenocarcinoma patients.
Luo M; Liu RZ; Li YJ; Zhang SD; Wu ZY
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9569-9585. PubMed ID: 37916324
[TBL] [Abstract][Full Text] [Related]
9. Exploring the role of the disulfidptosis-related gene SLC7A11 in adrenocortical carcinoma: implications for prognosis, immune infiltration, and therapeutic strategies.
Liu T; Ren Y; Wang Q; Wang Y; Li Z; Sun W; Fan D; Luan Y; Gao Y; Yan Z
Cancer Cell Int; 2023 Nov; 23(1):259. PubMed ID: 37919768
[TBL] [Abstract][Full Text] [Related]
10. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which
Xu K; Zhang Y; Yan Z; Wang Y; Li Y; Qiu Q; Du Y; Chen Z; Liu X
Front Immunol; 2023; 14():1205250. PubMed ID: 37426643
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
12. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
13. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
14. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis.
Liu X; Nie L; Zhang Y; Yan Y; Wang C; Colic M; Olszewski K; Horbath A; Chen X; Lei G; Mao C; Wu S; Zhuang L; Poyurovsky MV; James You M; Hart T; Billadeau DD; Chen J; Gan B
Nat Cell Biol; 2023 Mar; 25(3):404-414. PubMed ID: 36747082
[TBL] [Abstract][Full Text] [Related]
15. The levels of immunosuppressive checkpoint protein PD-L1 and tumor-infiltrating lymphocytes were integrated to reveal the glioma tumor microenvironment.
Zhang W; Liu L; Liu X; Han C; Li Q
Environ Toxicol; 2024 Feb; 39(2):815-829. PubMed ID: 37792606
[TBL] [Abstract][Full Text] [Related]
16. Analysis of long non-coding RNAs associated with disulfidptosis for prognostic signature and immunotherapy response in uterine corpus endometrial carcinoma.
Li B; Li X; Ma M; Wang Q; Shi J; Wu C
Sci Rep; 2023 Dec; 13(1):22220. PubMed ID: 38097686
[TBL] [Abstract][Full Text] [Related]
17. Exploring the role of disulfidptosis-related signatures in immune microenvironment, prognosis and therapeutic strategies of cervical cancer.
Jin T; Yin T; Xu R; Liu H; Yuan S; Xue Y; Zhang J; Wang H
Transl Oncol; 2024 Jun; 44():101938. PubMed ID: 38492499
[TBL] [Abstract][Full Text] [Related]
18. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
Chen X; Liang Q; Zhou Y
Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
20. PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.
Zhang H; Wang Y; Zhao Y; Liu T; Wang Z; Zhang N; Dai Z; Wu W; Cao H; Feng S; Zhang L; Cheng Q; Liu Z
CNS Neurosci Ther; 2022 Nov; 28(11):1748-1766. PubMed ID: 35855654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
